Pharma RSS Digest - 2026-05-04
Overview
Monday's pharma news flow was light, with just two substantive developments both centered on regulatory approvals and long-term clinical data. BioMarin reinforced its VOXZOGO franchise with extended follow-up data showing sustained efficacy and bone safety over up to eight years, while signaling near-term expansion into hypochondroplasia pending Phase 3 results. Across the Pacific, Australia granted its first approval for NIKTIMVO (axatilimab), a novel anti-CSF-1R antibody for chronic graft-versus-host disease, marking the first non-US authorization for the therapy and highlighting Australia's contribution to its discovery. The tape is thin today; the failed story about the Canton Fair has no bearing on pharma.
Key Developments
BioMarin Builds Long-Term Case for VOXZOGO with Eight-Year Data; Hypochondroplasia Expansion Nears
BioMarin presented new long-term extension trial data at the Pediatric Endocrine Society's 2026 Annual Meeting, demonstrating that children with achondroplasia treated with VOXZOGO (vosoritide) continued to show improved arm span and stable bone mineral density Z-scores over up to eight years of follow-up. Children treated after age 5 gained a mean of 10.60 cm after six years and 13.59 cm after eight years compared to untreated cohorts, with high statistical significance. A separate Phase 2 study in hypochondroplasia showed significant gains in bone mineral content and density after 12 months, providing mechanistic support for expansion. The company reaffirmed expectations for topline Phase 3 data (CANOPY-HCH-3) in hypochondroplasia during the first half of 2026, with a planned regulatory submission in the second half if results are positive. What to watch: whether the Phase 3 data lands cleanly and if the submission timeline holds, as this would substantially widen the addressable patient population for VOXZOGO beyond its current achondroplasia label.
Australia Approves NIKTIMVO for Refractory Chronic GVHD, First Non-US Authorization
NIKTIMVO (axatilimab) received TGA approval on May 3, 2026, for adults and children six years and older weighing at least 40 kg with chronic graft-versus-host disease after failure of at least two prior systemic therapies. Australia is the first country to grant marketing authorization since the FDA approved the drug in August 2024, with the approval based on the AGAVE-201 pivotal trial showing a 74% overall response rate and 60% of patients maintaining response at 12 months among 241 refractory patients. The therapy was developed through a collaboration including Incyte and Syndax, with Specialised Therapeutics holding commercial rights in Australia and pursuing PBS reimbursement. Australian researchers at QIMR Berghofer made the foundational discovery identifying the CSF-1R pathway as a driver of cGVHD. What to watch: PBS listing outcome and pricing negotiations, which will determine patient access breadth, as well as ongoing studies in frontline combination settings that could further expand the label.
Watchlist
- Canton Fair product zones (non-pharma announcement; summary incomplete) — unrelated to pharmaceutical industry developments and excluded from primary coverage. [link]